S100 family signaling network and related proteins in pancreatic cancer (Review)

Ji,Yi-Fei; Huang,Hua; Jiang,Feng; Ni,Run-Zhou; Xiao,Ming-Bing

doi:10.3892/ijmm.2014.1633

S100 family signaling network and related proteins in pancreatic cancer (Review)

Authors:
- Yi-Fei Ji
- Hua Huang
- Feng Jiang
- Run-Zhou Ni
- Ming-Bing Xiao
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: January 24, 2014 https://doi.org/10.3892/ijmm.2014.1633
Pages: 769-776

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The occurrence and development of pancreatic cancer is a complex process convoluted by multi-pathogenies, multi-stages and multi-factors. S100 proteins are members of the S100 family that regulate multiple cellular pathways related to pancreatic cancer progression and metastasis. S100 proteins have a broad range of intracellular and extracellular functions, including the regulation of protein phosphorylation and enzyme activity, calcium homeostasis and the regulation of cytoskeletal components and transcriptional factors. S100 proteins interact with receptor for advanced glycation end-products (RAGE), p53 and p21, which play a role in the degradation of the extracellular matrix (ECM) and metastasis, and also interact with cytoskeletal proteins and the plasma membrane in pancreatic cancer progression and metastasis. S100A11 and S100P are significant tumor markers for pancreatic cancer and unfavorable predictors for the prognosis of patients who have undergone surgical resection. Recently, S100A2 has been suggested to be a negative prognostic biomarker in pancreatic cancer, and the expression of S100A6 may be an independent prognostic impact factor. The expression of S100A4 and S100P is associated with drug resistance, differentiation, metastasis and clinical outcome. This review summarizes the role and significance of the S100 family signaling network and related proteins in pancreatic cancer.

View Figures

View References

1	Li N, Song MM, Chen XH, Liu LH and Li FS: S100A4 siRNA inhibits human pancreatic cancer cell invasion in vitro. Biomed Environ Sci. 25:465–470. 2012.PubMed/NCBI
2	Arumugam T and Logsdon CD: S100P: a novel therapeutic target for cancer. Amino acids. 41:893–899. 2011. View Article : Google Scholar
3	Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F and Ni RZ: The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 138:1035–1043. 2012. View Article : Google Scholar : PubMed/NCBI
4	Danovi SA, Wong HH and Lemoine NR: Targeted therapies for pancreatic cancer. Br Med Bull. 87:97–130. 2008. View Article : Google Scholar : PubMed/NCBI
5	Rezvanpour A and Shaw GS: Unique S100 target protein interactions. Gen Physiol Biophys. 28:F39–F46. 2009.
6	Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN and Cheng L: Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 27:3051–3058. 2007.PubMed/NCBI
7	Salama I, Malone PS, Mihaimeed F and Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol. 34:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
8	Donato R: S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 33:637–668. 2001. View Article : Google Scholar : PubMed/NCBI
9	Marenholz I, Heizmann CW and Fritz G: S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 322:1111–1122. 2004. View Article : Google Scholar : PubMed/NCBI
10	Moore BW: A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 19:739–744. 1965. View Article : Google Scholar : PubMed/NCBI
11	Zimmer DB, Cornwall EH, Landar A and Song W: The S100 protein family: history, function, and expression. Brain Res Bull. 37:417–429. 1995. View Article : Google Scholar : PubMed/NCBI
12	Berge G and Mælandsmo GM: Evaluation of potential interactions between the metastasis-associated protein S100A4 and the tumor suppressor protein p53. Amino Acids. 41:863–873. 2011. View Article : Google Scholar : PubMed/NCBI
13	Komatsu K, Kobune-Fujiwara Y, Andoh A, et al: Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer. 83:769–774. 2000. View Article : Google Scholar : PubMed/NCBI
14	Melle C, Ernst G, Schimmel B, Bleul A and Eggeling FV: Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(²⁺)-binding proteins S100A6 and S100A11. PloS One. 3:e37672008. View Article : Google Scholar : PubMed/NCBI
15	Schäfer BW and Heizmann CW: The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci. 21:134–140. 1996.PubMed/NCBI
16	Mishra SK, Siddique HR and Saleem M: S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev. 31:163–172. 2012. View Article : Google Scholar : PubMed/NCBI
17	Heizmann CW, Ackermann GE and Galichet A: Pathologies involving the S100 proteins and RAGE. Subcell Biochem. 45:93–138. 2007. View Article : Google Scholar : PubMed/NCBI
18	Saleem M, Kweon MH, Johnson JJ, et al: S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA. 103:14825–14830. 2006. View Article : Google Scholar : PubMed/NCBI
19	Gross SR, Sin CG, Barraclough R and Rudland PS: Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci. 30:June 30–2013.(Epub ahead of print).
20	Sorci G, Riuzzi F, Giambanco I and Donato R: RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 1833:101–109. 2012. View Article : Google Scholar
21	Xie J, Méndez JD, Méndez-Valenzuela and Aguilar-Hernández MM: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 25:2185–2197. 2013. View Article : Google Scholar : PubMed/NCBI
22	Maletzki C, Bodammer P, Breitrück A and Kerkhoff C: S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon. 12:e72402012.PubMed/NCBI
23	Volz HC, Laohachewin D, Seidel C, et al: S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-κB signaling. Basic Res Cardiol. 107:2502012.PubMed/NCBI
24	Hung KW, Chang YM and Yu C: Resonance assignments of Ca²⁺-bound human S100A11. Biomol NMR Assign. 7:211–214. 2013. View Article : Google Scholar
25	Arumugam T, Ramachandran V, Gomez SB, Schmidt AM and Logsdon CD: S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res. 18:4356–4364. 2012. View Article : Google Scholar : PubMed/NCBI
26	Arumugam T, Ramachandran V, Sun D, et al: Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Mol Cancer Ther. 12:654–662. 2013. View Article : Google Scholar : PubMed/NCBI
27	Ohuchida K, Mizumoto K, Miyasaka Y, et al: Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol. 213:275–282. 2007. View Article : Google Scholar : PubMed/NCBI
28	Leclerc E, Fritz G, Weibel M, Heizmann CW and Calichet A: S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem. 282:31317–31331. 2007. View Article : Google Scholar : PubMed/NCBI
29	Leclerc E and Heizmann CW: The importance of Ca²⁺/Zn²⁺ signaling S100 proteins and RAGE in translational medicine. Front Biosci (Schol Ed). 3:1232–1262. 2011.
30	Filipek A, Michowski W and Kuznicki J: Involvement of S100A6 (calcyclin) and its binding partners in intracellular signaling pathways. Adv Enzyme Regul. 48:225–239. 2008. View Article : Google Scholar : PubMed/NCBI
31	Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R and Rauuala H: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem. 275:40096–40105. 2000. View Article : Google Scholar : PubMed/NCBI
32	Taguchi A, Blood DC, del Toro G, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 405:354–360. 2000. View Article : Google Scholar : PubMed/NCBI
33	Lukanidin E and Sleeman JP: Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol. 22:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
34	Chen H, Fernig DG, Rudland PS, Sparks A, Wilkinson MC and Barraclough R: Binding to intracellular targets of the metastasis-inducing protein, S100A4 (p9Ka). Biochem Biophys Res Commun. 286:1212–1217. 2001. View Article : Google Scholar : PubMed/NCBI
35	Kriajevska MV, Cardenas MN, Grigorian MS, Ambartsumian NS, Georgiev GP and Lukanidin EM: Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem. 269:19679–19682. 1994.PubMed/NCBI
36	Zimmer DB and Van Eldik LJ: Analysis of the calcium-modulated proteins, S100 and calmodulin, and their target proteins during C6 glioma cell differentiation. J Cell Biol. 108:141–151. 1989. View Article : Google Scholar : PubMed/NCBI
37	Zhao XQ, Naka M, Muneyuki M and Tanaka T: Ca(2+)-dependent inhibition of actin-activated myosin ATPase activity by S100C (S100A11), a novel member of the S100 protein family. Biochem Biophys Res Commun. 267:77–79. 2000.
38	Broome AM and Eckert RL: Microtubule-dependent redistribution of a cytoplasmic cornified envelope precursor. J Invest Dermatol. 122:29–38. 2004. View Article : Google Scholar : PubMed/NCBI
39	Hayes MJ, Shao D, Bailly M and Moss SE: Regulation of actin dynamics by annexin 2. EMBO J. 25:1816–1826. 2006. View Article : Google Scholar : PubMed/NCBI
40	de Graauw M, Tijdens I, Smeets MB, et al: Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin activation. Mol Cell Biol. 28:1029–1040. 2008.PubMed/NCBI
41	Rust RR, Baldisseri DM and Weber DJ: Structure of the negative regulatory domain of p53 bound to S100B (betabeta). Nat Struct Biol. 7:570–574. 2000. View Article : Google Scholar : PubMed/NCBI
42	Kato K, Kamada H, Fujimori T, Aritomo Y, Ono M and Masaki T: Molecular biologic approach to the diagnosis of pancreatic carcinoma using specimens obtained by EUS-guided fine needle aspiration. Gastroenterol Res Pract. 2012:2435242012. View Article : Google Scholar : PubMed/NCBI
43	Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med. 11:1306–1313. 2005. View Article : Google Scholar : PubMed/NCBI
44	Green ML, Pisano MM, Prough RA and Knudsen TB: Release of targeted p53 from the mitochondrion as an early signal during mitochondrial dysfunction. Cell Signal. 25:2383–2390. 2013. View Article : Google Scholar : PubMed/NCBI
45	Leśniak W, Słomnicki LP and Filipek A: S100A6-new facts and features. Biochem Biophys Res Commun. 390:1087–1092. 2009.
46	Van Dieck J, Lum JK and Fersht AR: S100 proteins interact with the N-terminal domain of MDM2. FEBS Letts. 584:3269–3274. 2010.PubMed/NCBI
47	Wolf S, Haase-Kohn C and Pietzsch J: S100A2 in cancerogenesis: a friend or a foe? Amino Acids. 41:849–861. 2011. View Article : Google Scholar : PubMed/NCBI
48	Nishioku T, Furusho K, Tomita A, et al: Potential role for S100A4 in the disruption of the blood-brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis. Neuroscience. 189:286–292. 2011. View Article : Google Scholar : PubMed/NCBI
49	Sapkota D, Costea DE, Blø M, Bruland O, Lorens JB, Vasstrand EN and Ibrahim SO: S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncol. 48:219–225. 2012. View Article : Google Scholar : PubMed/NCBI
50	Grigorian M, Andresen S, Tulchinsky E, et al: Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem. 276:22699–22708. 2001. View Article : Google Scholar : PubMed/NCBI
51	Shimamoto S, Kubota Y, Yamaguchi F, Tokumitsu H and Kobayashi R: Ca²⁺/S100 proteins act as upstream regulators of the chaperone-associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein). J Biol Chem. 288:7158–7168. 2013.
52	Romanov VS, Pospelov VA and Pospelova TV: Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry (Mosc). 77:575–584. 2012. View Article : Google Scholar : PubMed/NCBI
53	Sakaguchi M, Miyazaki M, Takaishi M, et al: S100C/A11 is a key mediator of Ca(²⁺)-induced growth inhibition of human epidermal keratinocytes. J Cell Biol. 163:825–835. 2003.PubMed/NCBI
54	Li B, Wan X, Zhu Q, et al: Net expression inhibits the growth of pancreatic ductal adenocarcinoma cell PL45 in vitro and in vivo. PloS One. 8:e578182013. View Article : Google Scholar : PubMed/NCBI
55	Sakaguchi M and Huh NH: S100A11, a dual growth regulator of epidermal keratinocytes. Amino Acids. 41:797–807. 2011. View Article : Google Scholar : PubMed/NCBI
56	He H, Li J, Weng S, LI M and Yu Y: S100A11: diverse function and pathology corresponding to different target proteins. Cell Biochem Biophys. 55:117–126. 2009. View Article : Google Scholar : PubMed/NCBI
57	Ohuchida K, Mizumoto K, Ohhashi S, et al: S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res. 12:5417–5422. 2006. View Article : Google Scholar : PubMed/NCBI
58	Mann K and Hainaut P: Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene. 24:3964–3975. 2005. View Article : Google Scholar : PubMed/NCBI
59	Brain JG, Robertson H, Thompson E, et al: Biliary epithelial senescence and plasticity in acute cellular rejection. Am J Transplant. 13:1688–1702. 2013. View Article : Google Scholar : PubMed/NCBI
60	Yang SY, Miah A, Pabari A and Winslet M: Growth Factors and their receptors in cancer metastases. Front Biosci (Landmark Ed). 16:531–538. 2011. View Article : Google Scholar : PubMed/NCBI
61	Jia W, Gao XJ, Yang ZX and Zhang ZD: S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci. 17:1495–1508. 2013.PubMed/NCBI
62	Chen H, Yuan Y, Zhang C, et al: Involvement of S100A14 protein in cell invasion by affecting expression and function of matrix metalloproteinase (MMP)-2 via p53-dependent transcriptional regulation. J Biol Chem. 287:17109–17119. 2012. View Article : Google Scholar : PubMed/NCBI
63	Gebhardt C, Németh J, Angel P and Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 72:1622–1631. 2006. View Article : Google Scholar : PubMed/NCBI
64	Hsu TC, Young MR, Cmarik J and Colburn NH: Activator 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med. 28:1338–48. 2000. View Article : Google Scholar : PubMed/NCBI
65	Bachet JB, Maréchal R, Demetter P, et al: S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Eur J Cancer. 49:2643–53. 2013. View Article : Google Scholar : PubMed/NCBI
66	Jamieson NB, Carter CR, McKay CJ and Oien KA: Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 17:3316–3331. 2011. View Article : Google Scholar : PubMed/NCBI
67	Biankin AV, Kench JG, Colvin EK, et al: Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology. 137:558–568. 2009. View Article : Google Scholar : PubMed/NCBI
68	Russo SM, Ove R and Saif MW: Identification of prognostic and predictive markers in pancreatic adenocarcinoma. In: Highlights from the ‘2011 ASCO Gastrointestinal Cancers Sympsoium’; San Francisco, CA, USA. January 20–22, 2011; JOP. 12. pp. 92–95. 2011, PubMed/NCBI
69	Sekine H, Chen N, Sato K, et al: S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochem Biophys Res Commun. 429:214–219. 2012. View Article : Google Scholar : PubMed/NCBI
70	Ilg EC, Schäfer BW and Heizmann CW: Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer. 68:325–332. 1996. View Article : Google Scholar : PubMed/NCBI
71	Tsukamoto N, Egawa S, Akada M, et al: The expression of S100A4 in human pancreatic cancer is associated with invasion. Pancreas. 42:1027–1033. 2013. View Article : Google Scholar : PubMed/NCBI
72	Chang D, Colvin E, Scarlett C, et al: A molecular prognostic nomogram for resectable pancreatic cancer. J Clin Oncol. 29(Suppl 4): abs. 154. 2011.
73	Ikenaga N, Ohuchida K, Mizumoto K, et al: S100A4 mRNA is a diagnostic and prognostic marker in pancreatic carcinoma. J Gastrointest Surg. 13:1852–1858. 2009. View Article : Google Scholar : PubMed/NCBI
74	Schneider G and Filipek A: S100A6 binding protein and Siah-1 interacting protein (CacyBP/SIP): spotlight on properties and cellular function. Amino Acids. 41:773–780. 2011. View Article : Google Scholar : PubMed/NCBI
75	Ohuchida K, Mizumoto K, Ishikawa N, et al: The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 11:7785–7793. 2005. View Article : Google Scholar : PubMed/NCBI
76	Ohuchida K, Mizumoto K, Yu J, et al: S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 16:649–654. 2007. View Article : Google Scholar
77	Vimalachandran D, Greenhalf W, Thompson C, et al: High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res. 65:3218–3225. 2005.PubMed/NCBI
78	Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al: Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 166:81–92. 2005. View Article : Google Scholar : PubMed/NCBI
79	Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB and Von Hoff DD: Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62:2890–2896. 2002.PubMed/NCBI
80	Ohuchida K, Mizumoto K, Egami T, et al: S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 12:5411–5416. 2006. View Article : Google Scholar : PubMed/NCBI
81	Nakata K, Nagai E, Ohuchida K, et al: S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum Pathol. 41:824–831. 2010. View Article : Google Scholar : PubMed/NCBI
82	Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al: Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol. 201:63–74. 2003. View Article : Google Scholar
83	Barry S, Chelala C, Lines K, et al: S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cell. Clin Exp Metastasis. 30:251–264. 2013. View Article : Google Scholar : PubMed/NCBI
84	Inada H, Naka M, Tanaka T, Davey GE and Heizmann CW: Human S100A11 exhibits differential steady-state RNA levels in various tissues and a distinct subcellular localization. Biochem Biophys Res Commun. 263:135–138. 1999. View Article : Google Scholar : PubMed/NCBI
85	Chen JH, Ni RZ, Xiao MB, Guo JG and Zhou JW: Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int. 8:193–200. 2009.PubMed/NCBI
86	Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T and Nexo E: Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res. 11:606–611. 2005.PubMed/NCBI
87	Nakashima T, Wang XF, Masuda M, Inokuchi A and Komiyama S: Overexpression of p53 nuclear protein in premalignant and malignant laryngeal lesions. Eur Arch Otorhinolaryngol. 256:S56–S59. 1999. View Article : Google Scholar : PubMed/NCBI
88	Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK and Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54:321–326. 1994.PubMed/NCBI
89	Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY and Ni RZ: High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med Oncol. 29:1886–1891. 2012. View Article : Google Scholar : PubMed/NCBI
90	Arumugam T, Simeone DM, Van Golen K and Logsdon CD: S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 11:5356–5364. 2005. View Article : Google Scholar : PubMed/NCBI